Most Recent
MFS execs lose appeal over $147.5M in misused funds
Three former executives of failed Gold Coast finance company MFS Group have lost their challenge to a ruling that they misappropriated $147.5 million in funds prior to the company's collapse.
Neurim fights to amend Circadin patent amid infringement case against generics
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
Privilege not waived by DLA Piper phone call over Circadin patent
Two generic drug makers have lost their bid for confidential documents related to Neurim Pharmaceuticals' patents covering sleep drug Circadin, with a court ruling legal professional privilege was waived in a phone conversation between a DLA Piper lawyer and the company's founder.
DLA Piper’s patent advice to Neurim not privileged, court hears
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company's founder and her lawyers from DLA Piper.
DibbsBarker to close up shop following Dentons deal
DibbsBarker is closing its doors after signing a deal that will see 17 partners and support staff move to Dentons, the world's largest firm.
Dentons grows Aussie presence with new Melbourne digs
Global law firm Dentons has expanded its presence in Australia with a fifth office Down Under, this one in Melbourne.
Competition lawyers brace for tougher enforcement
Lawyers are advising large companies to look hard at their business plans to keep on the good side of the Australian Competition and Consumer Commission now that the enforcer has a new arsenal to deploy.